Skip to main content
. 2016 Feb 23;4(2):e00212. doi: 10.1002/prp2.212

Figure 3.

Figure 3

Reduced levels of FGFR4 and related downstream genes induced by deguelin. (A) Real‐time reverse transcription‐PCR for FGFR4 was conducted to examine FGFR4 mRNA expression. Deguelin dose‐dependently suppressed FGFR4 release, which was validated by positive control group. Three individual experiments were conducted. Each bar indicates the mean ± SD. *P < 0.05; **P < 0.01;***P < 0.001 (t‐test). Each drug‐treated group was compared to respective control group with DMSO treatment to decide its significance. FGFR inhibitor SU5402 was used as a positive control. (B) Immunoblot was performed with specialized antibodies for FGFR4, p‐AKT, p‐ERK, and ERK to detect the protein levels. The results showed that deguelin inhibited FGFR4 expression and constitutive phosphorylation of AKT and ERK in zebrafish. FGFR inhibitor SU5402 was used as a positive control. Bar graph, Density analysis results from each concentration in western Blot. a.u. represent arbitrary units. *P < 0.05; **P < 0.01;***P < 0.001 (t‐test). Each drug‐treated group was compared to control group with DMSO treatment to decide its significance. FGFR4, fibroblast growth factor receptor 4; PCR, polymerase chain reaction; p‐AKT, phospho‐protein kinase B; p‐ERK, phospho‐extracellular regulated protein kinases; DMSO, dimethyl sulfoxide.